Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.

Original languageEnglish (US)
Pages (from-to)S53-S58
JournalClinical and experimental rheumatology
Volume17
Issue number6 SUPPL. 18
StatePublished - 1999

Keywords

  • Combination
  • DMARD
  • Hydroxychloroquine
  • Methotrexate
  • Rheumatoid arthritis
  • Sulfasalazine

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate'. Together they form a unique fingerprint.

Cite this